Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies

Table 2 Clinical, biochemical and demographic characteristics of Crohn’s disease patients with or without successful mucosal healing in response to anti-TNF-α therapy n (%)

Feature	All (n = 29)	MH-group (n = 18)	Non-MH group(n = 11)	MH vs non-MH
Change in Simple Endoscopic Score for Crohn’s disease over time (%)	-55 [-72-(-37)]	-70 [-81-(-56)]	-33 [-38-(-8)]	P < 0.0001
Age (yr)	27 (21-35)	22 (21-30)	35 (27-39)	P = 0.02
Men	21 (72)	15 (83)	5 (45)	P = 0.04
Disease duration (yr)	6 (3-11)	6 (5-10)	6 (3-12)	P = 0.77
Baseline Crohn’s disease Activity Index (n)	319 (298-420)	310 (240-397)	348 (301-440)	P = 0.26
Baseline Simple Endoscopic Score for Crohn’s disease (n)	15 (8-21)	16 (8-23)	12 (8-20)	P = 0.36
Baseline C-reactive protein (mg/L)	9.8 (2.8-31.2)	8.7 (2.3-18.2)	18.6 (3.7-34.5)	P = 0.15
Baseline hemoglobin (g/dL)	12.9 (10.1-14)	12 (9.9-13.5)	13.1 (10.2-14.8)	P = 0.60
Baseline albumin (mg/dL)	4.2 (3.6-4.4)	4.1 (3.5-4.4)	4.2 (3.7-4.4)	P = 0.84
Disease location
L1 (ileal)	3/29 (10)	1/18 (5)	2/11 (18)	P = 0.53
L2 (colonic)	9/29 (31)	5/18 (28)	4/11 (36)	P = 0.69
L3 (ileocolonic)	17/29 (59)	12/18 (67)	5/11 (46)	P = 0.43
Disease behavior
B1 (inflammatory)	24/29 (83)	14/18 (78)	10/11 (91)	P = 0.62
B2 (stricturing)	1/29 (3)	1/18 (5)	0/11 (0)	P = 1.00
B3 (penetrating)	4/29 (14)	3/18 (17)	1/11 (9)	P = 1.00
Medications
Steroids	19/29 (65)	10/18 (55)	9/11 (82)	P = 0.23
Azathioprine	15/29 (52)	12/18 (67)	3/11 (27)	P = 0.06
Aminosalicylates	28/29 (96)	18/18 (100)	10/11 (91)	P = 0.37
Anti-TNF-α agent used: adalimumab/infliximab	17/12 (59/41)	11/7 (61/39)	6/5 (55/45)	P = 0.51

The data are presented as medians with interquartile ranges. MH: Mucosal healing.